Michael. I. Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael. I. Miller has a total of 426 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Jacob Tward
Department of Computational Medicine, University of California Los Angeles, Los Angeles, USA
20 shared publications - Laurent Younes
Center for Imaging Science, Johns Hopkins University, Baltimore, USA
20 shared publications - John Tilak Ratnanather
Center for Imaging Science and Institute for Computational Medicine, Department of Biomedical Engineering, Johns Hopkins University
12 shared publications - Alain Trouvé
Centre Giovanni Borelli École Normale Supérieure Paris-Saclay Université Paris-Saclay F-91190 Gif-sur-Yvette France
8 shared publications - Anja Soldan
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
7 shared publications - Corinne Pettigrew
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
6 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214620
Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages
Changes in CSF and tau PET biomarkers of Alzheimer disease (AD) emerge years before clinical symptoms are observed. However, few studies have examined the temporal relationship between these measures. This study investigated whether longitudinal changes in CSF AD biomarkers were associated with 18F-MK6240 tau PET measures in early Braak stage subregions. This study involved a retrospective analysis of cognitively unimpaired participants from the longitudinal observational Biomarkers of Cognitive Decline Among Normal Individuals cohort (NIH and Johns Hopkins University). Phosphorylated tau (p-tau) 181, total tau (t-tau), and β-amyloid (Aβ)42/Aβ40) measures were obtained from CSF collected biennially over a mean of 12.8 years before tau PET acquisition. Linear mixed-effect models examined how previous CSF biomarker levels and rates of change in these measures related to subsequent tau deposition corresponding to Braak stages I and II. A total of 120 cognitively unimpaired individuals (baseline age range 32-78 years; mean age 57 years; 60% female) were included in the analysis, including 78 participants with longitudinal CSF data (424 observations) and 42 additional participants contributing to cross-sectional analyses of initial CSF levels only. Results showed that higher levels of CSF p-tau181 (β = 0.567 [0.411-0.724]; β = 0.508 [0.344-0.671]) and t-tau (β = 0.411 [0.260-0.562]; β = 0.393 [0.240-0.547]), as well as steeper previous rates of increase in p-tau181 (β = 0.016 [0.008-0.024]; β = 0.018 [0.011-0.025]) and t-tau (β = 0.015 [0.009-0.022]; β = 0.016 [0.010-0.022]), were significantly associated with subsequent higher tau PET burden in Braak stages I and II. By contrast, although lower Aβ42/Aβ40 levels were associated with subsequent tau burden (β = -0.556 [-0.706 to -0.406]; β = -0.503 [-0.653 to -0.353]), the rate of change in Aβ42/Aβ40 over time was not. These findings show that tau PET burden in Braak stage I and II subregions is associated with increases in CSF tau and p-tau over time, offering important insights into the relationships among key biomarkers for the diagnosis and staging of AD, although tau PET was collected at only a single time point, limiting inferences about the temporal evolution of PET-CSF relationships.
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214620
Open AccessAssociation Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages
Changes in CSF and tau PET biomarkers of Alzheimer disease (AD) emerge years before clinical symptoms are observed. However, few studies have examined the temporal relationship between these measures. This study investigated whether longitudinal changes in CSF AD biomarkers were associated with 18F-MK6240 tau PET measures in early Braak stage subregions. This study involved a retrospective analysis of cognitively unimpaired participants from the longitudinal observational Biomarkers of Cognitive Decline Among Normal Individuals cohort (NIH and Johns Hopkins University). Phosphorylated tau (p-tau) 181, total tau (t-tau), and β-amyloid (Aβ)42/Aβ40) measures were obtained from CSF collected biennially over a mean of 12.8 years before tau PET acquisition. Linear mixed-effect models examined how previous CSF biomarker levels and rates of change in these measures related to subsequent tau deposition corresponding to Braak stages I and II. A total of 120 cognitively unimpaired individuals (baseline age range 32-78 years; mean age 57 years; 60% female) were included in the analysis, including 78 participants with longitudinal CSF data (424 observations) and 42 additional participants contributing to cross-sectional analyses of initial CSF levels only. Results showed that higher levels of CSF p-tau181 (β = 0.567 [0.411-0.724]; β = 0.508 [0.344-0.671]) and t-tau (β = 0.411 [0.260-0.562]; β = 0.393 [0.240-0.547]), as well as steeper previous rates of increase in p-tau181 (β = 0.016 [0.008-0.024]; β = 0.018 [0.011-0.025]) and t-tau (β = 0.015 [0.009-0.022]; β = 0.016 [0.010-0.022]), were significantly associated with subsequent higher tau PET burden in Braak stages I and II. By contrast, although lower Aβ42/Aβ40 levels were associated with subsequent tau burden (β = -0.556 [-0.706 to -0.406]; β = -0.503 [-0.653 to -0.353]), the rate of change in Aβ42/Aβ40 over time was not. These findings show that tau PET burden in Braak stage I and II subregions is associated with increases in CSF tau and p-tau over time, offering important insights into the relationships among key biomarkers for the diagnosis and staging of AD, although tau PET was collected at only a single time point, limiting inferences about the temporal evolution of PET-CSF relationships.
- Open Access
- 6 January 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (2) , 100454
Hippocampal microstructure as a measure of cognitive resilience to tau PET burden in older adults
- 6 January 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (2) , 100454
Open AccessHippocampal microstructure as a measure of cognitive resilience to tau PET burden in older adults
- Open Access
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10398
Solving the where problem and quantifying geometric variation in neuroanatomy using generative diffeomorphic mapping
A current focus in neuroscience is to map neuronal cell types in whole vertebrate brains using different imaging modalities. Mapping modern molecular and anatomical datasets into a common atlas includes challenges that existing workflows do not adequately address: multimodal signals, missing data or non reference signals, and quantification of individual variation. Our solution implements a generative model describing the likelihood of data given a sequence of transforms of an atlas, and a maximum a posteriori estimation framework. Our approach allows composition of mappings across chains of datasets rather than only pairs, and computes metrics for geometric quantification. We study a range of datasets (in/ex-vivo MRI, STP and fMOST, 2D serial histology, snRNAseq prepared tissue), quantifying cell density and geometric fluctuations across covariates, and reveal that individual variation is often greater than differences due to tissue processing techniques. We provide open source code, dataset standards, and a web interface. This establishes a quantitative workflow for unifying multi-modal whole-brain images in an atlas framework, validated using mouse datasets, enabling large scale integration of datasets essential to modern neuroscience.
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10398
Open AccessSolving the where problem and quantifying geometric variation in neuroanatomy using generative diffeomorphic mapping
A current focus in neuroscience is to map neuronal cell types in whole vertebrate brains using different imaging modalities. Mapping modern molecular and anatomical datasets into a common atlas includes challenges that existing workflows do not adequately address: multimodal signals, missing data or non reference signals, and quantification of individual variation. Our solution implements a generative model describing the likelihood of data given a sequence of transforms of an atlas, and a maximum a posteriori estimation framework. Our approach allows composition of mappings across chains of datasets rather than only pairs, and computes metrics for geometric quantification. We study a range of datasets (in/ex-vivo MRI, STP and fMOST, 2D serial histology, snRNAseq prepared tissue), quantifying cell density and geometric fluctuations across covariates, and reveal that individual variation is often greater than differences due to tissue processing techniques. We provide open source code, dataset standards, and a web interface. This establishes a quantitative workflow for unifying multi-modal whole-brain images in an atlas framework, validated using mouse datasets, enabling large scale integration of datasets essential to modern neuroscience.
- Open Access
Predicting future cognitive impairment in preclinical Alzheimer’s disease using amyloid PET and MRI: a multisite machine learning study
Predicting the likelihood of developing Alzheimer’s disease (AD) dementia in at-risk individuals is important for the design of and optimal recruitment for clinical trials of disease-modifying therapies. Machine learning (ML) has been shown to excel in this task; however, there remains a lack of models developed specifically for the preclinical AD population, who display early signs of abnormal brain amyloidosis but remain cognitively unimpaired. Here, we trained and evaluated ML classifiers to predict whether individuals with preclinical AD will progress to mild cognitive impairment or dementia within multiple fixed time windows, ranging from one to five years. Models were trained on regional imaging features extracted from amyloid positron emission tomography and magnetic resonance imaging pooled across seven independent sites and from two amyloid radiotracers ([ 18 F]-florbetapir and [ 11 C]-Pittsburgh-compound-B). Out-of-sample generalizability was evaluated via a leave-one-site-out and leave-one-tracer-out cross-validation. Classifiers achieved an out-of-sample receiver operating characteristic area-under-the-curve of 0.66 or greater when applied to all except one hold-out sites and 0.72 or greater when applied to each hold-out radiotracer. Additionally, when applying our models in a retroactive cohort enrichment analysis on A4 clinical trial data, we observed increased statistical power of detecting differences in amyloid accumulation between placebo and treatment arms after enrichment by ML stratifications. As emerging investigations of new disease-modifying therapies for AD increasingly focus on asymptomatic, preclinical populations, our findings underscore the potential applicability of ML-based patient stratification for recruiting more homogeneous cohorts and improving statistical power for detecting treatment effects for future clinical trials. Highlights: Machine learning can predict future cognitive impairment in preclinical Alzheimer’s Models achieved high out-of-sample ROC-AUC on external sites and PET tracers Models were able to distinguish cognitively stable from decliners in the A4 cohort ML cohort enrichment enhanced secondary treatment effect detection in the A4 cohort
Open AccessPredicting future cognitive impairment in preclinical Alzheimer’s disease using amyloid PET and MRI: a multisite machine learning study
Predicting the likelihood of developing Alzheimer’s disease (AD) dementia in at-risk individuals is important for the design of and optimal recruitment for clinical trials of disease-modifying therapies. Machine learning (ML) has been shown to excel in this task; however, there remains a lack of models developed specifically for the preclinical AD population, who display early signs of abnormal brain amyloidosis but remain cognitively unimpaired. Here, we trained and evaluated ML classifiers to predict whether individuals with preclinical AD will progress to mild cognitive impairment or dementia within multiple fixed time windows, ranging from one to five years. Models were trained on regional imaging features extracted from amyloid positron emission tomography and magnetic resonance imaging pooled across seven independent sites and from two amyloid radiotracers ([ 18 F]-florbetapir and [ 11 C]-Pittsburgh-compound-B). Out-of-sample generalizability was evaluated via a leave-one-site-out and leave-one-tracer-out cross-validation. Classifiers achieved an out-of-sample receiver operating characteristic area-under-the-curve of 0.66 or greater when applied to all except one hold-out sites and 0.72 or greater when applied to each hold-out radiotracer. Additionally, when applying our models in a retroactive cohort enrichment analysis on A4 clinical trial data, we observed increased statistical power of detecting differences in amyloid accumulation between placebo and treatment arms after enrichment by ML stratifications. As emerging investigations of new disease-modifying therapies for AD increasingly focus on asymptomatic, preclinical populations, our findings underscore the potential applicability of ML-based patient stratification for recruiting more homogeneous cohorts and improving statistical power for detecting treatment effects for future clinical trials. Highlights: Machine learning can predict future cognitive impairment in preclinical Alzheimer’s Models achieved high out-of-sample ROC-AUC on external sites and PET tracers Models were able to distinguish cognitively stable from decliners in the A4 cohort ML cohort enrichment enhanced secondary treatment effect detection in the A4 cohort
- Open Access
- 30 September 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-22
The xIV-LDDMM toolkit of image-varifold based technologies for mapping 3D images and spatial-omics across scales
Advancements in imaging and molecular techniques enable the collection of subcellular-scale data. Diversity in measured features, resolution, and physical scope of capture across technologies and experimental protocols pose numerous challenges to integrating data with reference coordinate systems and across scales. This paper describes a collection of technologies that we have developed for mapping data across scales and modalities, such as genes to tissues, specifically in a 3D setting. Our collection of technologies include (i) an explicit censored data representation for the partial matching problem mapping whole brains to subsampled subvolumes, (ii) a multi, scale-space optimization technology for generating resampling grids optimized to represent spatial geometry at fixed complexities, and (iii) mutual-information based functional feature selection. We integrate these technologies with our cross-modality mapping algorithm through the use of image-varifold measure norms to represent universally data across scales and imaging modalities. Collectively, these methods afford efficient representations of peta-scale imagery providing the algorithms for mapping from the nano to millimeter scales, which we term cross-modality image-varifold LDDMM (xIV-LDDMM).
- 30 September 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-22
Open AccessThe xIV-LDDMM toolkit of image-varifold based technologies for mapping 3D images and spatial-omics across scales
Advancements in imaging and molecular techniques enable the collection of subcellular-scale data. Diversity in measured features, resolution, and physical scope of capture across technologies and experimental protocols pose numerous challenges to integrating data with reference coordinate systems and across scales. This paper describes a collection of technologies that we have developed for mapping data across scales and modalities, such as genes to tissues, specifically in a 3D setting. Our collection of technologies include (i) an explicit censored data representation for the partial matching problem mapping whole brains to subsampled subvolumes, (ii) a multi, scale-space optimization technology for generating resampling grids optimized to represent spatial geometry at fixed complexities, and (iii) mutual-information based functional feature selection. We integrate these technologies with our cross-modality mapping algorithm through the use of image-varifold measure norms to represent universally data across scales and imaging modalities. Collectively, these methods afford efficient representations of peta-scale imagery providing the algorithms for mapping from the nano to millimeter scales, which we term cross-modality image-varifold LDDMM (xIV-LDDMM).
- Open Access
xIV-LDDMM Toolkit: A Suite of Image-Varifold Based Technologies for Representing and Mapping 3D Imaging and Spatial-omics Data Simultaneously Across Scales
Advancements in imaging and molecular techniques enable the collection of subcellular-scale data. Diversity in measured features, resolution, and physical scope of capture across technologies and experimental protocols pose numerous challenges to integrating data with reference coordinate systems and across scales. This paper describes a collection of technologies that we have developed for mapping data across scales and modalities, such as genes to tissues, specifically in a 3D setting. Our collection of technologies include (i) an explicit censored data representation for the partial matching problem mapping whole brains to subsampled subvolumes, (ii) a multi, scale-space optimization technology for generating resampling grids optimized to represent spatial geometry at fixed complexities, and (iii) mutual-information based functional feature selection. We integrate these technologies with our cross-modality mapping algorithm through the use of image-varifold measure norms to represent universally data across scales and imaging modalities. Collectively, these methods afford efficient representations of peta-scale imagery providing the algorithms for mapping from the nano to millimeter scales, which we term cross-modality image-varifold LDDMM (xIV-LDDMM).
Open AccessxIV-LDDMM Toolkit: A Suite of Image-Varifold Based Technologies for Representing and Mapping 3D Imaging and Spatial-omics Data Simultaneously Across Scales
Advancements in imaging and molecular techniques enable the collection of subcellular-scale data. Diversity in measured features, resolution, and physical scope of capture across technologies and experimental protocols pose numerous challenges to integrating data with reference coordinate systems and across scales. This paper describes a collection of technologies that we have developed for mapping data across scales and modalities, such as genes to tissues, specifically in a 3D setting. Our collection of technologies include (i) an explicit censored data representation for the partial matching problem mapping whole brains to subsampled subvolumes, (ii) a multi, scale-space optimization technology for generating resampling grids optimized to represent spatial geometry at fixed complexities, and (iii) mutual-information based functional feature selection. We integrate these technologies with our cross-modality mapping algorithm through the use of image-varifold measure norms to represent universally data across scales and imaging modalities. Collectively, these methods afford efficient representations of peta-scale imagery providing the algorithms for mapping from the nano to millimeter scales, which we term cross-modality image-varifold LDDMM (xIV-LDDMM).
- Open Access
- 25 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Cross-modality mapping using image varifolds to align tissue-scale atlases to molecular-scale measures with application to 2D brain sections
This paper explicates a solution to building correspondences between molecular-scale transcriptomics and tissue-scale atlases. This problem arises in atlas construction and cross-specimen/technology alignment where specimens per emerging technology remain sparse and conventional image representations cannot efficiently model the high dimensions from subcellular detection of thousands of genes. We address these challenges by representing spatial transcriptomics data as generalized functions encoding position and high-dimensional feature (gene, cell type) identity. We map onto low-dimensional atlas ontologies by modeling regions as homogeneous random fields with unknown transcriptomic feature distribution. We solve simultaneously for the minimizing geodesic diffeomorphism of coordinates through LDDMM and for these latent feature densities. We map tissue-scale mouse brain atlases to gene-based and cell-based transcriptomics data from MERFISH and BARseq technologies and to histopathology and cross-species atlases to illustrate integration of diverse molecular and cellular datasets into a single coordinate system as a means of comparison and further atlas construction.
- 25 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Open AccessCross-modality mapping using image varifolds to align tissue-scale atlases to molecular-scale measures with application to 2D brain sections
This paper explicates a solution to building correspondences between molecular-scale transcriptomics and tissue-scale atlases. This problem arises in atlas construction and cross-specimen/technology alignment where specimens per emerging technology remain sparse and conventional image representations cannot efficiently model the high dimensions from subcellular detection of thousands of genes. We address these challenges by representing spatial transcriptomics data as generalized functions encoding position and high-dimensional feature (gene, cell type) identity. We map onto low-dimensional atlas ontologies by modeling regions as homogeneous random fields with unknown transcriptomic feature distribution. We solve simultaneously for the minimizing geodesic diffeomorphism of coordinates through LDDMM and for these latent feature densities. We map tissue-scale mouse brain atlases to gene-based and cell-based transcriptomics data from MERFISH and BARseq technologies and to histopathology and cross-species atlases to illustrate integration of diverse molecular and cellular datasets into a single coordinate system as a means of comparison and further atlas construction.
- Open Access
- 21 February 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Open Journal of Engineering in Medicine and Biology
- Vol. 5, 1-13
Grand Challenges at the Interface of Engineering and Medicine
Over the past two decades Biomedical Engineering has emerged as a major discipline that bridges societal needs of human health care with the development of novel technologies. Every medical institution is now equipped at varying degrees of sophistication with the ability to monitor human health in both non-invasive and invasive modes. The multiple scales at which human physiology can be interrogated provide a profound perspective on health and disease. We are at the nexus of creating “avatars” (herein defined as an extension of “digital twins”) of human patho/physiology to serve as paradigms for interrogation and potential intervention. Motivated by the emergence of these new capabilities, the IEEE Engineering in Medicine and Biology Society, the Departments of Biomedical Engineering at Johns Hopkins University and Bioengineering at University of California at San Diego sponsored an interdisciplinary workshop to define the grand challenges that face biomedical engineering and the mechanisms to address these challenges. The Workshop identified five grand challenges with cross-cutting themes and provided a roadmap for new technologies, identified new training needs, and defined the types of interdisciplinary teams needed for addressing these challenges. The themes presented in this paper include: 1) accumedicine through creation of avatars of cells, tissues, organs and whole human; 2) development of smart and responsive devices for human function augmentation; 3) exocortical technologies to understand brain function and treat neuropathologies; 4) the development of approaches to harness the human immune system for health and wellness; and 5) new strategies to engineer genomes and cells.
- 21 February 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Open Journal of Engineering in Medicine and Biology
- Vol. 5, 1-13
Open AccessGrand Challenges at the Interface of Engineering and Medicine
Over the past two decades Biomedical Engineering has emerged as a major discipline that bridges societal needs of human health care with the development of novel technologies. Every medical institution is now equipped at varying degrees of sophistication with the ability to monitor human health in both non-invasive and invasive modes. The multiple scales at which human physiology can be interrogated provide a profound perspective on health and disease. We are at the nexus of creating “avatars” (herein defined as an extension of “digital twins”) of human patho/physiology to serve as paradigms for interrogation and potential intervention. Motivated by the emergence of these new capabilities, the IEEE Engineering in Medicine and Biology Society, the Departments of Biomedical Engineering at Johns Hopkins University and Bioengineering at University of California at San Diego sponsored an interdisciplinary workshop to define the grand challenges that face biomedical engineering and the mechanisms to address these challenges. The Workshop identified five grand challenges with cross-cutting themes and provided a roadmap for new technologies, identified new training needs, and defined the types of interdisciplinary teams needed for addressing these challenges. The themes presented in this paper include: 1) accumedicine through creation of avatars of cells, tissues, organs and whole human; 2) development of smart and responsive devices for human function augmentation; 3) exocortical technologies to understand brain function and treat neuropathologies; 4) the development of approaches to harness the human immune system for health and wellness; and 5) new strategies to engineer genomes and cells.
- 22 December 2023
- Published by Elsevier in Medical Image Analysis
- Vol. 93, 103068
Space-feature measures on meshes for mapping spatial transcriptomics
- 22 December 2023
- Published by Elsevier in Medical Image Analysis
- Vol. 93, 103068
Space-feature measures on meshes for mapping spatial transcriptomics
- Open Access
- 8 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
STalign: Alignment of spatial transcriptomics data using diffeomorphic metric mapping
Spatial transcriptomics (ST) technologies enable high throughput gene expression characterization within thin tissue sections. However, comparing spatial observations across sections, samples, and technologies remains challenging. To address this challenge, we develop STalign to align ST datasets in a manner that accounts for partially matched tissue sections and other local non-linear distortions using diffeomorphic metric mapping. We apply STalign to align ST datasets within and across technologies as well as to align ST datasets to a 3D common coordinate framework. We show that STalign achieves high gene expression and cell-type correspondence across matched spatial locations that is significantly improved over landmark-based affine alignments. Applying STalign to align ST datasets of the mouse brain to the 3D common coordinate framework from the Allen Brain Atlas, we highlight how STalign can be used to lift over brain region annotations and enable the interrogation of compositional heterogeneity across anatomical structures. STalign is available as an open-source Python toolkit at https://github.com/JEFworks-Lab/STalign and as Supplementary Software with additional documentation and tutorials available at https://jef.works/STalign.
- 8 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Open AccessSTalign: Alignment of spatial transcriptomics data using diffeomorphic metric mapping
Spatial transcriptomics (ST) technologies enable high throughput gene expression characterization within thin tissue sections. However, comparing spatial observations across sections, samples, and technologies remains challenging. To address this challenge, we develop STalign to align ST datasets in a manner that accounts for partially matched tissue sections and other local non-linear distortions using diffeomorphic metric mapping. We apply STalign to align ST datasets within and across technologies as well as to align ST datasets to a 3D common coordinate framework. We show that STalign achieves high gene expression and cell-type correspondence across matched spatial locations that is significantly improved over landmark-based affine alignments. Applying STalign to align ST datasets of the mouse brain to the 3D common coordinate framework from the Allen Brain Atlas, we highlight how STalign can be used to lift over brain region annotations and enable the interrogation of compositional heterogeneity across anatomical structures. STalign is available as an open-source Python toolkit at https://github.com/JEFworks-Lab/STalign and as Supplementary Software with additional documentation and tutorials available at https://jef.works/STalign.